Abstract Objective: The aim of this post-hoc analysis was to evaluate the effect of depression severity on clinical response in patients with bipolar depression treated with lurasidone. Methods: Patients with bipolar I depression in 2 registration trials were randomized to 6 weeks of once-daily, double-blind, placebo-controlled treatment with lurasidone monotherapy (20-60 mg/d or 80-120 mg/d; N=499); or with lurasidone adjunctive to lithium or valproate (20-120 mg/d; N=345). Two baseline depression severity groups were defined post-hoc: a moderate (Montgomery-Asberg Depression Rating Scale [MADRS] total score: 20-29) and a high (MADRS≥30) severity group. For each group, changes in MADRS total score were analyzed using a mixed model for repeated measures analysis. Results: In the monotherapy study, 42.9% of patients were in the moderate severity group (mean MADRS total score: 26.0) and 57.1% were in the high severity group (MADRS: 33.9). In the adjunctive therapy study, 39.7% of patients were in the moderate severity group (mean MADRS: 25.7) and 60.3% were in the high severity group (MADRS: 34.0). In the monotherapy study, lurasidone vs. placebo effect sizes (Cohen's d) for MADRS change at week 6 in the high severity vs. moderate severity groups were d=0.60 (P<0.001) vs. 0.40 (P=0.035) for the 20-60 mg/d dose range, and d=0.55 (P=0.002) vs. 0.50 (P=0.008) for the 80-120 mg/d dose range; and in the adjunctive therapy study, effect sizes for MADRS change in the high severity vs. moderate severity groups were d=0.25 (P=0.10) vs. d=0.41 (P=0.033). A treatment by baseline severity interaction test was non-significant for both the monotherapy and adjunctive therapy studies. Conclusions: In this post-hoc analysis, the magnitude of endpoint improvement in depressive symptoms vs. placebo was comparable for patients with both moderate and high levels of baseline depression severity during for both monotherapy and adjunctive therapy with lurasidone.
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Psychotropic medication for bipolar patients in the psychiatric acute inpatient unit.
Hiroki Sasamori, Hiroki Yamada, Akira Yoshizawa, Kouichi Jinbo, Sachiko Yokoyama, Yuzuru Ishibe, Teppei Morita, Osamu Takashio, Tokyo, Japan Abstract Objective: In Japan, there are many regulation of national health insurance to the psychiatric acute inpatient unit. For example over 60% patients must be legal forced hospitalization on admission and have to discharge within 3 months. Therefore differences between medication in the psychiatric acute inpatient unit with guidelines crarify actual clinical medication. Method: We researched medication of bipolar disorder in the psychiatric acute inpatient units in Karasuyama Hospital. All patients admitted between 2010 and 2013 were retrospectively followed through medical records. We investigated the use of antipsychotics, moodstabilizers, antidepressants and benzodiazepines to bipolar disorder on admission and discharge. Results: 1899 patients admitted to psychiatric acute inpatient units of Karasuama Hospital and 221 patients were bipolar disorder diagnosed by ICD-10. 78 patients were manic phase and 112 patients were depressive phase on admission. Mood stabilizer and antipsychotics had been respectively prescribed 59.7% and 76.5% on admission, and 75.1% and 83.3% on discharge. Over 70% of bipolar patients discharged within 3 months.
Conclusion:
It was more useful to use antipsychotics than mood stabilizer when the start of treatment in the actual clinical medication to bipolar disorder. While there are differences from guidelines the treatment of bipolar disorder had been largely successful on the rules of national health insurance in the psychiatric acute inpatient unit of Karasuyama Hospital. It is necessary to clarify the difference between the evidences and actual clinical medication.
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Prescription Patterns for Bipolar Disorders in a Psychiatric Hospital in Japan We investigated the change in prescription patterns for bipolar disorders in our hospital during the latest five years. We also studied the difference in the prescription patterns between bipolar I (BD-I) and II (BD-II) disorders. Methods: We used the prescription data of all the outpatients with bipolar disorders in the time period from 2010 to 2015 in our hospital.
Data were collected at two index dates for each year (April 1 and October 1).
Collected data: age, gender, prescribed mood stabilizers (MS), antipsychotics (AS) and/or antidepressants (AD) and their doses, and diagnosis.
This study was approved by the ethical committe board of Kusatsu Hospital. Results: We identified 1971 patients (bipolarBD-I:53.1%, BD-II: 46.9%).
During the surveyed period, the proportion of the patients for whom any MS(s) was prescribed decreased from 88.2% to 84.4%. Similarly, the proportion changed from 25.2% to 52.1 % for AS(s), and from 29.9% to 27.8% for AD(s).
For the same period, MS monotherapy decreased from 51.2% to 31.6%, whereas combination therapy of MS(s) and AP(s) increased from 14.2% to 31.6％.
AP monotherapy also increased from 2.4% to 7.2％. AD(s) and lamotrigine were significantly more frequently prescribed for the patients with BP-II than BP-I. Conclusions: We found a significant change in the prescription pattern for bipolar disorders in our hospital over the last five years.
The treatment guidelines might have resulted in the more frequent prescription of antipsychotics, although it did not seem to affect the prescription of AD(s).
The result might suggest the need for differential strategies in the pharmacotherapy of BP-I and BP-II.
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Association of ANK3 Variants with Bipolar Disorder in the Korean Population: a case-control haplotype analysis
